Context Therapeutics (NASDAQ:CNTX) Rating Increased to Strong-Buy at Lifesci Capital

Context Therapeutics (NASDAQ:CNTX) was upgraded by Lifesci Capital to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

A number of other research analysts also recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a report on Wednesday, January 21st. HC Wainwright lifted their price objective on Context Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. D. Boral Capital reissued a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research note on Thursday, November 6th. Wall Street Zen upgraded Context Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 16th. Finally, JonesTrading initiated coverage on shares of Context Therapeutics in a report on Monday, December 22nd. They issued a “buy” rating and a $7.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $6.00.

Context Therapeutics Trading Up 1.8%

CNTX stock opened at $2.28 on Monday. The stock has a market capitalization of $209.49 million, a price-to-earnings ratio of -9.50 and a beta of 1.93. The firm’s 50-day moving average price is $1.80 and its two-hundred day moving average price is $1.31. Context Therapeutics has a 12-month low of $0.49 and a 12-month high of $2.85.

Institutional Investors Weigh In On Context Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CNTX. State Street Corp lifted its position in Context Therapeutics by 8.5% during the fourth quarter. State Street Corp now owns 165,607 shares of the company’s stock valued at $243,000 after buying an additional 13,000 shares during the period. Blue Owl Capital Holdings LP grew its position in shares of Context Therapeutics by 0.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock worth $10,926,000 after buying an additional 25,000 shares during the period. Virtu Financial LLC bought a new position in shares of Context Therapeutics in the 4th quarter worth about $43,000. Clear Harbor Asset Management LLC lifted its position in Context Therapeutics by 60.5% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after acquiring an additional 35,000 shares during the period. Finally, Quadrature Capital Ltd bought a new stake in Context Therapeutics during the fourth quarter worth about $68,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.